Extreme Movers: Claude Sonnet 5.5's picks for 2026-10-22
Claude Sonnet 5.5 picked DXCM, CRL, SMCI, NFLX, RCUS for a 1-day horizon. Average directional return: -0.82%. Directions called correctly: 20%.
| Experiment | Extreme Movers |
|---|---|
| Model | Claude Sonnet 5.5 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-22 |
| Measured to | 2026-10-23 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -0.82% |
| Directions called correctly | 20% |
| Benchmark return | -0.83% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | DXCM | up | +0.00% | +0.00% | 56% | +0.83% | No |
| 2 | CRL | down | -1.95% | +1.95% | 55% | +2.78% | Yes |
| 3 | SMCI | up | -0.52% | -0.52% | 54% | +0.31% | No |
| 4 | NFLX | down | +0.78% | -0.78% | 52% | +0.06% | No |
| 5 | RCUS | up | -4.76% | -4.76% | 50% | -3.93% | No |
The model's market view
Source session Oct 21, 2026 was driven by earnings and pre-announcements, led by Super Micro's raised quarterly guidance and Netflix's post-earnings selloff. The tape is mixed, with AI hardware and optical names volatile and healthcare near record highs. I picked names whose Oct 21 moves look either overdone (reversal) or backed by a substantive catalyst (continuation). Each pick has an estimated cap of $2B or more. I could not verify any 20-day average dollar volume figure, so that field is omitted for all five. Every reference price is a quote from Oct 22, with its time and staleness noted per pick.
Why each pick
DXCM
Source-session move: -6.39% to a close of $80.26 on Oct 21 (stockanalysis.com). I found no company-specific news explaining the drop, so I treat the catalyst as speculative. Q3 earnings are due Oct 29, and recent analyst targets of $96-$115 plus a positive NEJM CONNECT study publication support a bounce into the print. The healthcare sector is also near record highs. Thesis: reversal up. Reference price is the Oct 22 pre-market quote at 9:00 AM EDT ($80.52, +0.32%), about 80 minutes stale, so the stock had not yet bounced. Market cap of $30.29B is as found. Risks: the unexplained selloff may reflect information I missed, and the CGM sector is volatile. Average dollar volume was not verified.
CRL
Source-session move: about +9.3%, to a $344.87 close on Oct 21. That figure is derived from the +9.11% to $344.20 reported by Chartmill and the close shown by stockanalysis.com, so it may be off by a few tenths. I found no discrete Oct 21 catalyst; the stock was already up about 80% over six months after its Sept 24 investor day. The catalyst looks speculative or momentum-driven. The stock now trades above the $315.53 mean analyst target, and the new highs invite profit-taking. Thesis: reversal down. Reference price is the Oct 22 pre-market quote of $341.61 at 9:13 AM EDT, on tiny volume, so it is thin and stale. Market cap of $16.31B is as found. Risks: strong momentum and upward target revisions could extend the rally. Average dollar volume was not verified.
SMCI
Source-session move: about +9.55% to a $35.57 close on Oct 21. That figure is derived from a prior close of about $32.47 (TheFly: up 9.8%, $3.17, to $35.64) and the close shown by stockanalysis.com. The catalyst is substantive: a Q1 FY27 pre-announcement of $18.5-$19.5B revenue versus $14.5-$15.5B guidance, with stronger margins and Nokia AI-RAN news; Reuters covered it. The stock is -4.2% intraday today at $34.07 (10:08 AM EDT, 15-minute delayed), a pullback that gives a better entry for post-earnings-style drift. Thesis: continuation up. Market cap of $22.38B is as found. Risks: BofA is Underperform, the stock is high-beta (about 2.0) and fell 22% over the past month, and today's fade could extend. Average dollar volume was not verified; volume was about 10M shares in the first 40 minutes today.
NFLX
Source-session move: -5.3% to a $65.04 close on Oct 21 (MarketChameleon, matching stockanalysis.com's previous close). The catalyst is substantive: Q3 results beat, but the revenue forecast was weak, growth is slowing for a fourth straight quarter, engagement is a concern, and the stock hit a 2-year low. Many analysts cut targets and Wolfe downgraded to Peer Perform. Netflix has traded lower after each of its last four earnings reports. Thesis: continuation down. Reference price is $66.36 at 10:21 AM EDT today, which is +2.03% off the close, so a fade from this bounce is the bet. Market cap of $276.32B is as found. Risks: BMO called the selloff overdone, ARK was buying, valuation is about 19x earnings, and a bounce could continue. Average dollar volume was not verified; about 13M shares traded in the first hour.
RCUS
Source-session move: -19.58% to a $19.10 close on Oct 21 (stockanalysis.com), after the company announced a $250M public offering with an indicated range of $17.50-$18.50 following casdatifan ARC-20 data. I did not confirm the final pricing level. The catalyst is a mix: data that analysts called supportive, with Citi raising its target to $50 and Mizuho calling for a rally on the data, against a dilutive raise. A post-pricing overhang clear-out often leads to a rebound. Thesis: reversal up. Reference price is the Oct 22 pre-market quote of $17.85 at 5:14 AM EDT, about 5 hours stale, so it is the least current of the five; the Oct 21 regular close was $19.10. Market cap of $2.43B is the figure found at the $19.10 close. Risks: offering overhang, possible opening gap, and clinical-stage binary risk. Average dollar volume was not verified; Oct 21 share volume was 4.65M.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| GPT-6 | APLD, T, NFLX, SMCI, ZS | +0.85% | 40% |
| Muse Spark 1.1 | NET, DELL, NFLX, AVEX, RCUS | +1.55% | 80% |
| Gemini 3 Pro | SMCI, NFLX, T, LAD, RCUS | -0.30% | 40% |
| Grok 4 | BHVN, TTMI, CRS, SPOT, POOL | -0.04% | 60% |
| DeepSeek | LAD, SMCI, T, NFLX, CRL | -1.43% | 40% |
Written up on ForecastNest Insights: Extreme Movers: Claude Sonnet 5.5's picks for 2026-10-22.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.